Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
Similar Articles
Supreme Court Maintains Telehealth Access to Abortion Pill Mifepristone
Supreme Court Extends Telemedicine Access to Abortion Pill Mifepristone Through Thursday
Supreme Court Temporarily Blocks Nationwide Ban on Telemedicine Abortion Access
Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Reinstates In-Person Requirement
Federal Appeals Court Reinstates In-Person Requirement for Mifepristone
The Supreme Court has issued a one-week stay, temporarily blocking a lower court ruling that would have restricted access to the abortion drug mifepristone. The stay, issued by Justice Samuel Alito, preserves telehealth and mail-order prescribing until next Monday evening. Parties in the underlying lawsuit have until Thursday to submit briefs to the Court.
Facts First
- Supreme Court Justice Samuel Alito issued a one-week stay on Monday, blocking an appeals court ruling that would have restricted mifepristone access.
- The stay temporarily restores telehealth and mail-order prescribing of the abortion drug until Monday, May 11, at 5 p.m.
- The 5th U.S. Circuit Court of Appeals ruled on Friday that the FDA must revert to requiring in-person prescriptions for mifepristone.
- The appeals court sided with Louisiana in its lawsuit challenging Biden administration rules that expanded mifepristone access.
- All parties in the lawsuit must file briefs by Thursday in response to the Supreme Court's stay.
What Happened
On Friday, the 5th U.S. Circuit Court of Appeals ruled that the Food and Drug Administration (FDA) must revert to rules requiring in-person prescriptions for the abortion drug mifepristone, effectively banning telehealth and mail-order access nationwide. In response, the drug's manufacturers, Danco Laboratories and GenBioPro, requested emergency relief from the Supreme Court. On Monday, Justice Samuel Alito issued a stay, blocking the appeals court decision from taking effect for at least one week, until Monday, May 11, at 5 p.m. This action temporarily restores the previous rules allowing telehealth and mail-order prescribing.
Why this Matters to You
If you or someone you know relies on telehealth services for medication abortion, the current system of access remains in place for at least the next week. This may provide a window to obtain prescriptions under the existing rules. However, the lack of public guidance regarding prescriptions already written could create uncertainty for patients and providers. The legal challenge, brought by the state of Louisiana, argues that expanded access undermines state laws and has led to increased state Medicaid spending on emergency care, which could influence future healthcare policy and funding in other states.
What's Next
All parties involved in the underlying lawsuit have until Thursday, May 7, at 5 p.m. to submit briefs to the Supreme Court. The Court will then review these submissions and decide how to proceed after the current stay expires next Monday. The Supreme Court's next move could either extend the stay, hear the case on its merits, or allow the appeals court ruling to take effect. Federal judges have not yet issued decisions on Louisiana's underlying legal argument against the FDA rules, so the core legal dispute remains unresolved.